Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Pharmacology

Background:

• Severe COVID pneumonia involves significant inflammation, prompting guideline recommendations for tocilizumab alongside dexamethasone.
• Concerns persist regarding the risk of secondary infections with tocilizumab, despite trial data not showing a significant increase.

Purpose of the Study:

• To investigate the rate of secondary infections in severe COVID pneumonia patients treated with tocilizumab and dexamethasone.
• To compare secondary infection rates between patients receiving tocilizumab plus dexamethasone and those receiving dexamethasone alone.

Main Methods:

• A retrospective chart review compared patients with severe COVID pneumonia who received tocilizumab and dexamethasone (n=62) to those who received only dexamethasone (n=49).
• Tocilizumab was administered to patients with worsening acute hypoxic respiratory failure.
• Secondary infections were confirmed by positive cultures.

Main Results:

• Patients receiving tocilizumab experienced significantly higher rates of culture-positive secondary infections (45.5%) compared to controls (24.5%).
• Gram-negative bacterial pneumonias were more than twice as common in the tocilizumab group (30.3% vs. 14.3%).
• Mortality was 47.0% in the tocilizumab group, with 45.2% of deaths associated with secondary infections.

Conclusions:

• Real-world data suggests tocilizumab treatment for severe COVID pneumonia is associated with high rates of secondary infections.
• While tocilizumab's mortality benefit is established, the increased infection risk warrants further investigation.
• Future studies should explore dose-reduction strategies for tocilizumab to mitigate infection risk without compromising efficacy.